JP2020512387A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020512387A5 JP2020512387A5 JP2019554000A JP2019554000A JP2020512387A5 JP 2020512387 A5 JP2020512387 A5 JP 2020512387A5 JP 2019554000 A JP2019554000 A JP 2019554000A JP 2019554000 A JP2019554000 A JP 2019554000A JP 2020512387 A5 JP2020512387 A5 JP 2020512387A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- group
- salt
- methoxy
- halogen atoms
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 125000005843 halogen group Chemical group 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 11
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 7
- 125000001424 substituent group Chemical group 0.000 claims 7
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 5
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 5
- 150000001875 compounds Chemical class 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 5
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 3
- 125000006376 (C3-C10) cycloalkyl group Chemical group 0.000 claims 2
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 125000004430 oxygen atom Chemical group O* 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 125000000547 substituted alkyl group Chemical group 0.000 claims 2
- 229940124597 therapeutic agent Drugs 0.000 claims 2
- 125000000027 (C1-C10) alkoxy group Chemical group 0.000 claims 1
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 claims 1
- VPWLGFYYENMIJN-UHFFFAOYSA-N 2-[6-[[1-[2-(4,4-difluorocyclohexyl)-5-methoxyphenyl]piperidin-4-yl]methoxy]-3,4-dihydro-2H-pyrano[2,3-c]pyridin-4-yl]acetic acid Chemical compound FC1(CCC(CC1)C1=C(C=C(C=C1)OC)N1CCC(CC1)COC=1C=C2C(=CN=1)OCCC2CC(=O)O)F VPWLGFYYENMIJN-UHFFFAOYSA-N 0.000 claims 1
- RNXKXGJQIJOZKB-UHFFFAOYSA-N 2-[6-[[1-[2-methoxy-5-(2,2,3,3,3-pentafluoropropoxy)pyridin-4-yl]piperidin-4-yl]methoxy]-3,4-dihydro-2H-pyrano[2,3-c]pyridin-4-yl]acetic acid Chemical compound COC1=NC=C(C(=C1)N1CCC(CC1)COC=1C=C2C(=CN=1)OCCC2CC(=O)O)OCC(C(F)(F)F)(F)F RNXKXGJQIJOZKB-UHFFFAOYSA-N 0.000 claims 1
- RUTVCFGEHGHNTC-UHFFFAOYSA-N 2-[6-[[1-[2-methoxy-5-(3,3,3-trifluoropropyl)pyridin-4-yl]piperidin-4-yl]methoxy]-3,4-dihydro-2H-pyrano[2,3-c]pyridin-4-yl]acetic acid Chemical compound COC1=NC=C(C(=C1)N1CCC(CC1)COC=1C=C2C(=CN=1)OCCC2CC(=O)O)CCC(F)(F)F RUTVCFGEHGHNTC-UHFFFAOYSA-N 0.000 claims 1
- MSNQHFOESVRSCV-UHFFFAOYSA-N 2-[6-[[1-[5-methoxy-2-(3,3,3-trifluoropropyl)phenyl]piperidin-4-yl]methoxy]-3,4-dihydro-2H-pyrano[2,3-c]pyridin-4-yl]acetic acid Chemical compound COC=1C=CC(=C(C=1)N1CCC(CC1)COC=1C=C2C(=CN=1)OCCC2CC(=O)O)CCC(F)(F)F MSNQHFOESVRSCV-UHFFFAOYSA-N 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims 1
- GGMOOVNOBGCWKO-UHFFFAOYSA-N CC(CN(C(=O)C1=C(C=C(C=C1)OC)N1CCC(CC1)COC=1C=C2C(=CN=1)OCCC2CC(=O)O)C1=NC(=CC=C1)C)(C)C Chemical compound CC(CN(C(=O)C1=C(C=C(C=C1)OC)N1CCC(CC1)COC=1C=C2C(=CN=1)OCCC2CC(=O)O)C1=NC(=CC=C1)C)(C)C GGMOOVNOBGCWKO-UHFFFAOYSA-N 0.000 claims 1
- 102100026148 Free fatty acid receptor 1 Human genes 0.000 claims 1
- 101000912510 Homo sapiens Free fatty acid receptor 1 Proteins 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 125000005415 substituted alkoxy group Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017072813 | 2017-03-31 | ||
| JP2017072813 | 2017-03-31 | ||
| PCT/JP2018/014501 WO2018182050A1 (en) | 2017-03-31 | 2018-03-29 | Substituted cyclyl-acetic acid derivatives for the treatment of metabolic disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020512387A JP2020512387A (ja) | 2020-04-23 |
| JP2020512387A5 true JP2020512387A5 (enExample) | 2021-04-30 |
Family
ID=62116518
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019554000A Ceased JP2020512387A (ja) | 2017-03-31 | 2018-03-29 | 代謝性障害の治療の為の置換シクリル酢酸誘導体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10968231B2 (enExample) |
| EP (1) | EP3601260A1 (enExample) |
| JP (1) | JP2020512387A (enExample) |
| KR (1) | KR20190136049A (enExample) |
| CN (1) | CN110678458A (enExample) |
| AR (1) | AR111199A1 (enExample) |
| CA (1) | CA3058588C (enExample) |
| MX (1) | MX2019011782A (enExample) |
| TW (1) | TW201841920A (enExample) |
| WO (1) | WO2018182050A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11186565B2 (en) | 2017-03-31 | 2021-11-30 | Takeda Pharmaceutical Company Limited | Aromatic compound |
| BR102018007822A2 (pt) | 2017-04-20 | 2018-11-06 | Gilead Sciences, Inc. | composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição |
| WO2019160882A1 (en) | 2018-02-13 | 2019-08-22 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| KR102591947B1 (ko) | 2018-04-19 | 2023-10-25 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| PE20210642A1 (es) | 2018-07-13 | 2021-03-23 | Gilead Sciences Inc | Inhibidores de pd-1/pd-l1 |
| US11236085B2 (en) | 2018-10-24 | 2022-02-01 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| EP3978485B1 (en) | 2019-05-31 | 2026-02-11 | Hyundai Pharm Co., Ltd. | Novel crystal form of 3-(4-(benzyloxy)phenyl)hex-4-inoic acid derivative |
| JP2022552655A (ja) | 2019-10-07 | 2022-12-19 | キャリーオペ，インク． | Ｇｐｒ１１９アゴニスト |
| MX2022010548A (es) | 2020-02-28 | 2022-09-23 | Kallyope Inc | Agonistas de gpr40. |
| MX2022014505A (es) | 2020-05-19 | 2022-12-13 | Kallyope Inc | Activadores de la ampk. |
| TWI894280B (zh) * | 2020-05-26 | 2025-08-21 | 南韓商愛思阿爾法數字醫療科技有限公司 | 用以治療癌症惡病質之系統、用以治療癌症惡病質之運算系統及其操作方法、以及非暫態電腦可讀取媒體 |
| CA3183575A1 (en) | 2020-06-26 | 2021-12-30 | Iyassu Sebhat | Ampk activators |
| CN112830933A (zh) * | 2021-02-04 | 2021-05-25 | 康化（上海）新药研发有限公司 | 一种3,4-二氢-2H-吡喃并[2,3-b]吡啶合成方法 |
| KR102699076B1 (ko) * | 2021-04-01 | 2024-08-27 | 현대약품 주식회사 | 3-(4-(벤질옥시)페닐)헥스-4-이노익산 유도체의 신규 용도 |
| JPWO2023106310A1 (enExample) * | 2021-12-07 | 2023-06-15 |
Family Cites Families (43)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1072649C (zh) | 1995-09-13 | 2001-10-10 | 武田药品工业株式会社 | 苯并氧杂吖庚因化合物,其生产方法和用途 |
| AR035016A1 (es) | 1999-08-25 | 2004-04-14 | Takeda Chemical Industries Ltd | Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima. |
| EP1302462A4 (en) | 2000-07-17 | 2007-07-18 | Takeda Pharmaceutical | SULFONATE DERIVATIVES, PROCESS FOR PRODUCTION AND USE THEREOF |
| BR0315815A (pt) | 2002-11-01 | 2005-09-13 | Takeda Pharmaceutical | Agentes para prevenir ou tratar neuropatia, para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor, neuroprotetor e farmacêutico, composto, métodos para prevenir ou tratar neuropatia e para promover a produção ou a secreção de um fator neurotrópico, para melhorar a dor para proteger um nervo em um mamìfero e para produzir um composto e uso de um composto |
| AU2003277576A1 (en) * | 2002-11-08 | 2004-06-07 | Takeda Pharmaceutical Company Limited | Receptor function controlling agent |
| US20070004736A1 (en) | 2002-11-22 | 2007-01-04 | Keiji Kubo | Imidazole derivative, process for producing the same, and use |
| US7820837B2 (en) | 2003-05-30 | 2010-10-26 | Takeda Pharmaceutical Company Limited | Condensed ring compound |
| JP4805552B2 (ja) * | 2003-05-30 | 2011-11-02 | 武田薬品工業株式会社 | 縮合環化合物 |
| EP1669352A4 (en) | 2003-09-30 | 2008-12-17 | Takeda Pharmaceutical | THIAZOLINE DERIVATIVE AND ITS USE |
| WO2005058823A1 (ja) | 2003-12-17 | 2005-06-30 | Takeda Pharmaceutical Company Limited | ウレア誘導体、その製造法及び用途 |
| US7456218B2 (en) | 2003-12-25 | 2008-11-25 | Takeda Pharmaceutical Company Limited | 3-(4-benzyloxyphenyl) propanoic acid derivatives |
| WO2005063725A1 (ja) | 2003-12-26 | 2005-07-14 | Takeda Pharmaceutical Company Limited | フェニルプロパン酸誘導体 |
| WO2005087710A1 (ja) | 2004-03-15 | 2005-09-22 | Takeda Pharmaceutical Company Limited | アミノフェニルプロパン酸誘導体 |
| JP4859665B2 (ja) | 2004-03-30 | 2012-01-25 | 武田薬品工業株式会社 | アルコキシフェニルプロパン酸誘導体 |
| TWI396686B (zh) | 2004-05-21 | 2013-05-21 | Takeda Pharmaceutical | 環狀醯胺衍生物、以及其製品和用法 |
| US8957070B2 (en) | 2005-04-20 | 2015-02-17 | Takeda Pharmaceutical Company Limited | Glucokinase activator compounds, methods of activating glucokinase and methods of treating diabetes and obesity |
| EP1916234B1 (en) | 2005-07-29 | 2014-11-12 | Takeda Pharmaceutical Company Limited | Cyclopropanecarboxylic acid compound |
| US20090054435A1 (en) | 2005-07-29 | 2009-02-26 | Hiroshi Imoto | Phenoxyalkanoic Acid Compound |
| JP4094660B1 (ja) | 2005-08-10 | 2008-06-04 | 武田薬品工業株式会社 | 糖尿病治療剤 |
| JP2007063225A (ja) | 2005-09-01 | 2007-03-15 | Takeda Chem Ind Ltd | イミダゾピリジン化合物 |
| AU2007225208A1 (en) * | 2006-03-14 | 2007-09-20 | Amgen Inc. | Bicyclic carboxylic acid derivatives useful for treating metabolic disorders |
| AU2007265966B2 (en) | 2006-06-27 | 2012-05-17 | Takeda Pharmaceutical Company Limited | Fused cyclic compounds |
| EP2298772A1 (en) | 2006-10-18 | 2011-03-23 | Takeda Pharmaceutical Company Limited | Fused heterocyclic compounds |
| CN101573357B (zh) | 2006-10-19 | 2013-01-23 | 武田药品工业株式会社 | 吲哚化合物 |
| WO2008093639A1 (ja) | 2007-01-29 | 2008-08-07 | Takeda Pharmaceutical Company Limited | ピラゾール化合物 |
| AU2008215490A1 (en) | 2007-02-09 | 2008-08-21 | Takeda Pharmaceutical Company Limited | Fused ring compounds as partial agonists of PPAR-gamma |
| JPWO2008136428A1 (ja) | 2007-04-27 | 2010-07-29 | 武田薬品工業株式会社 | 含窒素５員複素環化合物 |
| EP2157859A4 (en) | 2007-06-19 | 2011-01-12 | Takeda Pharmaceutical | INDAZOL COMPOUNDS FOR THE ACTIVATION OF GLUCCOKINASE |
| JP5591706B2 (ja) | 2007-10-10 | 2014-09-17 | アムジエン・インコーポレーテツド | 置換ビフェニルｇｐｒ４０調節因子 |
| WO2009111056A1 (en) | 2008-03-06 | 2009-09-11 | Amgen Inc. | Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders |
| AU2009303475B2 (en) | 2008-10-15 | 2012-09-13 | Amgen Inc. | Spirocyclic GPR40 modulators |
| JP2013523819A (ja) * | 2010-04-06 | 2013-06-17 | アリーナ ファーマシューティカルズ， インコーポレイテッド | Ｇｐｒ１１９レセプターのモジュレーターおよびそれに関連する障害の処置 |
| WO2013122029A1 (ja) | 2012-02-13 | 2013-08-22 | 武田薬品工業株式会社 | 芳香環化合物 |
| ES2672992T3 (es) | 2013-08-09 | 2018-06-19 | Takeda Pharmaceutical Company Limited | Compuesto aromático |
| US9920040B2 (en) | 2015-08-12 | 2018-03-20 | Janssen Pharmaceutica Nv | GPR40 agonists for the treatment of type II diabetes |
| WO2017027310A1 (en) | 2015-08-12 | 2017-02-16 | Janssen Pharmaceutica Nv | Gpr40 agonists for the treatment of type ii diabetes |
| US9856245B2 (en) | 2015-08-12 | 2018-01-02 | Janssen Pharmaceutica Nv | GPR40 agonists for the treatment of type II diabetes |
| JP6627397B2 (ja) | 2015-10-09 | 2020-01-08 | 富士通オプティカルコンポーネンツ株式会社 | 光モジュール及び光伝送装置 |
| EP3436003B1 (en) | 2016-03-29 | 2023-08-23 | Merck Sharp & Dohme LLC | Antidiabetic bicyclic compounds |
| WO2018081047A1 (en) | 2016-10-25 | 2018-05-03 | Janssen Pharmaceutica Nv | Cyclohexyl gpr40 agonists for the treatment of type ii diabetes |
| WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| US11186565B2 (en) | 2017-03-31 | 2021-11-30 | Takeda Pharmaceutical Company Limited | Aromatic compound |
-
2018
- 2018-03-28 AR ARP180100764A patent/AR111199A1/es unknown
- 2018-03-29 KR KR1020197032237A patent/KR20190136049A/ko not_active Abandoned
- 2018-03-29 EP EP18722743.4A patent/EP3601260A1/en not_active Withdrawn
- 2018-03-29 MX MX2019011782A patent/MX2019011782A/es unknown
- 2018-03-29 TW TW107110982A patent/TW201841920A/zh unknown
- 2018-03-29 US US16/497,141 patent/US10968231B2/en not_active Expired - Fee Related
- 2018-03-29 JP JP2019554000A patent/JP2020512387A/ja not_active Ceased
- 2018-03-29 WO PCT/JP2018/014501 patent/WO2018182050A1/en not_active Ceased
- 2018-03-29 CN CN201880023454.7A patent/CN110678458A/zh active Pending
- 2018-03-29 CA CA3058588A patent/CA3058588C/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5985611B2 (ja) | 炎症および免疫関連用途のための化合物 | |
| JP2009523146A5 (enExample) | ||
| JP2010504913A5 (enExample) | ||
| JP2008513515A5 (enExample) | ||
| JP2016535772A5 (enExample) | ||
| JP2018127459A5 (enExample) | ||
| JP2016525130A5 (enExample) | ||
| KR102212981B1 (ko) | 4-알키닐이미다졸 유도체 및 그것을 유효 성분으로서 함유하는 의약 | |
| JP2014507464A5 (enExample) | ||
| JP2013129675A5 (enExample) | ||
| JP2018515581A5 (enExample) | ||
| JP2017502940A5 (enExample) | ||
| JP2015143283A5 (enExample) | ||
| EP2948147A1 (en) | N-substituted-5-substituted phthalamic acids as sortilin inhibitors | |
| JP2004529161A5 (enExample) | ||
| JP2011137006A5 (enExample) | ||
| JP2016525075A5 (enExample) | ||
| JP2005509003A5 (enExample) | ||
| JP2008504304A5 (enExample) | ||
| KR20210005668A (ko) | Hpk1 억제제, 그의 제조 방법 및 응용 | |
| JP2007500719A5 (enExample) | ||
| JP2010525023A5 (enExample) | ||
| JP2006522035A5 (enExample) | ||
| JP2017538689A5 (enExample) | ||
| JP2011513410A5 (enExample) |